---
title: "Caplin Point Laboratories Ltd (CAPLIPOINT) — Share Price, Financials & Analysis"
symbol: "CAPLIPOINT"
company: "Caplin Point Laboratories Ltd"
canonical: "https://tapetide.com/stocks/CAPLIPOINT"
isin: "INE475E01026"
nse_symbol: "CAPLIPOINT"
bse_code: "524742"
sector: "Healthcare"
industry: "Pharmaceuticals"
market_cap_cr: 20690.38
generated_at: "2026-09-13T18:56:59.615Z"
---

# Caplin Point Laboratories Ltd (CAPLIPOINT)

Canonical page: https://tapetide.com/stocks/CAPLIPOINT

## Company

- **NSE Symbol:** CAPLIPOINT
- **BSE Code:** 524742
- **ISIN:** INE475E01026
- **Sector:** Healthcare
- **Industry:** Pharmaceuticals
- **Macro Sector:** Healthcare
- **Stock Type:** EQUITY
- **Listed Since:** 1994-11-16
- **CEO:** Dr. Sridhar Ganesan
- **Employees:** 3966
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** caplinpoint.net

## About

Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations.[1]

## Latest Price

- **Price:** ₹2754.9
- **Change:** -40.5 (-1.45%)
- **Open:** ₹2790.1
- **Day High:** ₹2790.1
- **Day Low:** ₹2716
- **Previous Close:** ₹2795.4
- **Volume:** 103090
- **As Of:** 2026-09-11T10:23:04+00:00

## Key Fundamentals

Observed at 2026-09-11T04:42:23.642229Z.

- **Market Cap:** ₹20690.38 Cr
- **Classification:** Smallcap
- **P/E (reported):** 31.3
- **P/E (TTM):** 31.47
- **EPS (TTM):** ₹87.53
- **EPS (reported):** ₹62.84
- **Book Value:** ₹443.33
- **Price to Book:** 6.3
- **Dividend Yield:** 0.29%
- **ROE:** 17.89%
- **ROCE:** 21.96%
- **Debt to Equity:** 0.07
- **Revenue (yearly):** ₹2302.7 Cr
- **Net Income:** ₹649.7 Cr
- **EBITDA:** ₹876.4 Cr
- **52-Week High:** ₹2877.3
- **52-Week Low:** ₹1500.3
- **RSI (14):** 62.55

## Tapetide Score

- **Score:** 63 / 100
- **Score date:** 2026-09-04
- **Archetype:** Quality at a Reasonable Price
- **What it means:** Financial strength is not being paid for with a demanding multiple. The question worth asking is whether the quality is durable or reflects a good patch — check the consistency of returns over several years rather than the latest quarter.
- **Pillar profile:** Quality: Good · Valuation: Cheap · Momentum: Rising
- **Percentile:** 94.2 (of 4473 scored stocks)
- **Confidence:** 100%
- **Data coverage:** 100%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 86.25 | 9% |
| growth | 40.39 | 9% |
| momentum | 89.91 | 12% |
| ownership | 46.9 | 24% |
| quality | 64.42 | 22% |
| valuation | 68.64 | 24% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Company has delivered good profit growth of 21.4% CAGR over last 5 years
- Company's median sales growth is 19.9% of last 10 years

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | 21.02% | 64.34% | 55.39% |
| ebitda margin growth | 6.19% | 4.13% | 8.4% | 14.88% |
| net income growth | 3.59% | 20.07% | 19% | 21% |
| revenue growth | 2.45% | 13.22% | 14% | 16% |
| roce | 5.43% | -5.91% | -8.04% | 23.6% |
| roe | 3.59% | -4.59% | 18.77% | -12.43% |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 410 | 436 | 453 | 459 | 483 | 493 | 502 | 510 | 534 | 543 | 600 | 610 |
| Expenses | 273 | 293 | 308 | 307 | 318 | 331 | 334 | 332 | 345 | 353 | 396 | 397 |
| Operating Profit | 137 | 142 | 145 | 152 | 165 | 162 | 168 | 178 | 189 | 190 | 204 | 213 |
| OPM % | 34 | 33 | 32 | 33 | 34 | 33 | 33 | 35 | 35 | 35 | 34 | 35 |
| Other Income | 21 | 17 | 17 | 19 | 21 | 31 | 26 | 23 | 30 | 34 | 28 | 34 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 12 | 14 | 16 | 16 | 17 | 16 | 17 | 16 | 18 | 19 | 19 | 22 |
| Profit before tax | 146 | 145 | 146 | 154 | 168 | 177 | 177 | 184 | 201 | 204 | 213 | 225 |
| Tax % | 20 | 18 | 17 | 19 | 22 | 21 | 18 | 18 | 20 | 19 | 19 | 20 |
| Net Profit | 116 | 120 | 121 | 125 | 131 | 140 | 145 | 151 | 160 | 166 | 173 | 179 |
| EPS in Rs | 15.13 | 15.43 | 16.01 | 16.31 | 17.21 | 18.28 | 18.76 | 20.1 | 20.32 | 21.56 | 22.38 | 23.27 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 540 | 649 | 863 | 1061 | 1269 | 1467 | 1694 | 1937 | 2187 | 2287 |
| Expenses | 345 | 417 | 603 | 732 | 874 | 1025 | 1142 | 1287 | 1422 | 1491 |
| Operating Profit | 195 | 232 | 260 | 329 | 395 | 442 | 552 | 651 | 765 | 797 |
| OPM % | 36 | 36 | 30 | 31 | 31 | 30 | 33 | 34 | 35 | 35 |
| Other Income | 13 | 19 | 41 | 23 | 38 | 55 | 66 | 92 | 111 | 126 |
| Interest | 1 | 1 | 0 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Depreciation | 19 | 23 | 32 | 37 | 47 | 45 | 53 | 66 | 73 | 78 |
| Profit before tax | 188 | 227 | 269 | 314 | 386 | 451 | 564 | 677 | 803 | 844 |
| Tax % | 23 | 22 | 20 | 20 | 20 | 16 | 18 | 20 | 19 | — |
| Net Profit | 145 | 177 | 215 | 251 | 308 | 377 | 461 | 541 | 650 | 678 |
| EPS in Rs | 19.15 | 23.35 | 28.42 | 32.03 | 39.56 | 49.57 | 60.19 | 70.56 | 84.36 | 87.53 |
| Dividend Payout % | 10 | 9 | 9 | 9 | 10 | 9 | 8 | 8 | 9 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 | 15 |
| Reserves | 210 | 349 | 582 | 858 | 954 | 1252 | 1649 | 2084 | 2619 | 3355 |
| Borrowings | 1 | 1 | 36 | 113 | 235 | 219 | 222 | 219 | 222 | 221 |
| Other Liabilities | 133 | 136 | 109 | 139 | 159 | 250 | 305 | 380 | 352 | 446 |
| Total Liabilities | 358 | 500 | 743 | 1126 | 1364 | 1736 | 2191 | 2698 | 3208 | 4038 |
| Fixed Assets | 152 | 169 | 227 | 272 | 305 | 287 | 280 | 453 | 546 | 580 |
| CWIP | 3 | 15 | 10 | 20 | 14 | 18 | 221 | 117 | 144 | 234 |
| Investments | 17 | 47 | 70 | 61 | 11 | 89 | 281 | 376 | 590 | 859 |
| Other Assets | 186 | 269 | 436 | 772 | 1033 | 1343 | 1410 | 1753 | 1928 | 2365 |
| Total Assets | 358 | 500 | 743 | 1126 | 1364 | 1736 | 2191 | 2698 | 3208 | 4038 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 68 | 66 | 83 | 45 | 269 | 337 | 271 | 318 | 432 | 523 |
| Cash from Investing Activity | -36 | -69 | -100 | -54 | -30 | -377 | -216 | -319 | -333 | -582 |
| Cash from Financing Activity | -7 | -12 | 90 | 80 | -24 | -41 | -28 | -38 | -38 | -46 |
| Net Cash Flow | 25 | -14 | 73 | 70 | 215 | -81 | 27 | -39 | 61 | -105 |
| Free Cash Flow | 43 | 18 | 18 | -32 | 195 | 246 | 78 | 173 | 241 | 275 |
| CFO/OP | 73 | 53 | 54 | 38 | 102 | 106 | 81 | 77 | 86 | 87 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 30 | 85 | 90 | 97 | 96 | 91 | 98 | 117 | 119 | 138 |
| Inventory Days | 44 | 44 | 47 | 210 | 139 | 149 | 159 | 183 | 159 | 181 |
| Days Payable | 155 | 144 | 76 | 57 | 68 | 102 | 84 | 116 | 103 | 125 |
| Cash Conversion Cycle | -81 | -16 | 61 | 251 | 166 | 138 | 173 | 184 | 175 | 194 |
| Working Capital Days | -29 | 47 | 104 | 167 | 145 | 165 | 144 | 166 | 174 | 199 |
| ROCE % | 68 | 63 | 45 | 33 | 28 | 28 | 26 | 26 | 26 | 24 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 70.63% | 70.62% | 70.62% | 70.56% | 70.56% | 70.56% | 70.56% | 70.56% | 70.57% | 70.57% | 70.57% | 70.57% |
| FIIs | 3.09% | 2.85% | 3.34% | 3.37% | 3.7% | 4.86% | 5.73% | 6.17% | 6.51% | 6.59% | 6.15% | 5.75% |
| DIIs | 0.2% | 0.43% | 1.09% | 1.49% | 1.84% | 2.11% | 2.01% | 2.22% | 2.1% | 2.05% | 2.14% | 2.49% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 18.31% | 18.36% | 17.59% | 17.5% | 17.12% | 15.77% | 15.11% | 14.32% | 14.2% | 14.13% | 14.46% | 14.62% |
| Others | 7.77% | 7.74% | 7.36% | 7.08% | 6.78% | 6.7% | 6.59% | 6.73% | 6.61% | 6.65% | 6.68% | 6.56% |
| No. of Shareholders | 78068 | 79438 | 81409 | 80411 | 96123 | 92702 | 96387 | 94169 | 93753 | 93705 | 93896 | 94385 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Strong Buy
- **Buy / Neutral / Sell:** 13 / 6 / 0

### Moving Averages — summary: **Strong Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 2746.24 | Buy |
| EMA (10) | 2730.76 | Buy |
| SMA (20) | 2635.89 | Buy |
| EMA (20) | 2674.19 | Buy |
| SMA (50) | 2599.27 | Buy |
| EMA (50) | 2566.16 | Buy |
| SMA (100) | 2352.1 | Buy |
| EMA (100) | 2397.44 | Buy |
| SMA (200) | 2063.71 | Buy |
| EMA (200) | 2218.75 | Buy |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 58.73 | Neutral |
| MACD (12,26,9) | 66.1 | Buy |
| Stochastic (14,3,3) | 71.38 | Neutral |
| ADX (14) | 25.41 | Buy |
| Williams %R (14) | -29.32 | Neutral |
| ATR (14) | 97.57 | High Volatility |
| ROC (12) | 9.48 | Buy |
| Stoch RSI (14) | 54.77 | Neutral |
| UO (7,14,28) | 56.42 | Neutral |

## Analyst Ratings

| Recommendation | Analysts | Share |
| --- | --- | --- |
| Buy | 2 | 100% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |

Based on 2 analyst ratings, observed at 2026-09-11T04:42:23.729912+00:00.

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-04 | [Letter To Shareholders](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=25c809e6-0790-4f3d-a768-7c112f1d0f32.pdf) |
| 2026-09-04 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7c10594f-219d-45ba-93cb-39ef8fab6c2f.pdf) |
| 2026-09-03 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d09ac7e9-0a81-4dcd-b5f8-ef6f4f4d4e44.pdf) |
| 2026-09-03 | [Notice Of The 35Th Annual General Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f7eb3873-c34a-4e39-b104-9adf443dbd06.pdf) |
| 2026-09-03 | [Business Responsibility and Sustainability Reporting (BRSR)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3888dea5-113b-473e-93e9-7b3fb47da76c.pdf) |
| 2026-09-02 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1b0a612e-336c-485b-8621-deef6693f3e5.pdf) |
| 2026-09-01 | [General Updates](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cc643cd6-de1a-4604-a4a9-20a1f065e2d8.pdf) |
| 2026-08-21 | [General Updates](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=afc6cb39-7c1b-440a-a7a6-37c299ead42b.pdf) |
| 2026-08-12 | [Board Meeting Outcome for Meeting Held On August 12 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e4084018-6a35-4932-8267-6202a136b8b9.pdf) |
| 2026-08-12 | [Corporate Action-Board approves Dividend](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c90db1a8-8168-4538-b3d0-e7165cf2dbc8.pdf) |

### Earnings Call Transcripts

| Date | Document |
| --- | --- |
| 2026-08-19 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ee6da382-4c8e-4a3f-9aeb-daebbf7d20f7.pdf) |
| 2026-05-21 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2a669bf0-35f6-4130-8554-5c025f919311.pdf) |
| 2026-02-11 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=59f6ce31-d901-4d01-89b2-9ee265816dae.pdf) |
| 2025-11-12 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=92ae23d9-65c0-49a7-9615-ab1442f6a19d.pdf) |
| 2025-08-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=85d773ee-a620-46ea-8f29-0c1a72cd2a3e.pdf) |
| 2025-05-22 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2a6d4995-6214-474e-8082-2c97831b37a6.pdf) |
| 2025-02-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=19d2fba8-78fc-4ab9-9c22-0f03546300bc.pdf) |
| 2024-11-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=57c926b7-b77f-4a99-a5ef-511782e4ad2d.pdf) |
| 2024-08-14 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e4979a1d-2a6e-4a67-8d44-bdf01abd7ba1.pdf) |
| 2024-05-23 | [Announcement under Regulation 30 (LODR)-Earnings Call Transcript](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=39c6f2a7-ef05-474f-8415-5d6f69a0e7ee.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-12 | [Results For Quarter Ended June 30 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d5b33dac-c4ed-4bce-b93b-9435c67264d8.pdf) |
| 2026-05-14 | [Financial Results For The Quarter And Year Ended March 31 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=af133d6a-4702-48d7-9327-b91aab7675f7.pdf) |
| 2026-02-05 | [Financial Results For The Quarter Ended December 31 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3cc91ea8-f706-4bfe-bca0-c849dfef634b.pdf) |
| 2025-11-05 | [Un-Audited Standalone And Consolidated Financial Results For The Quarter And Half Year Ended 30Th September 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8f886ccc-f499-4e93-899f-4995a326fff3.pdf) |
| 2025-08-07 | [Financial Results For The Quarter Ended June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e18ffab4-fe29-41aa-a4b8-a235793e22bf.pdf) |
| 2025-05-15 | [The Board Had Approved Interim Dividend For The Year Ended 31-03-2025 Along With The Audited Results. The Details Of The Same Is Enclosed Herewith.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=190e56ba-9111-43af-aeed-7d504b231382.pdf) |
| 2025-02-07 | [Financial Results For The Quarter Ended December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0a36a095-8554-4c14-bde2-44c98430b9fd.pdf) |
| 2024-11-07 | [Financials Results For The Quarter And Half-Year Ended September 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=773cfcec-4a44-4ac6-bd97-eed10ae85c6a.pdf) |
| 2024-08-07 | [Financial Results For The Quarter Ended June 30, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0e2a9dee-61f9-43e2-b1a8-8d636de71fb7.pdf) |
| 2024-05-16 | [Results For The Quarter And Year Ended March 31, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6da851a4-d027-43af-a02e-8dce67d34fec.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4d134212-8757-4da4-9573-4f26e422f957.pdf) |
| 2026-02-05 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f761aa80-9ccc-4e05-9554-153ba6062c17.pdf) |
| 2021-10-30 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=30f8d312-3f19-490f-b564-5eec109e3ae3.pdf) |

### Earnings Call Recordings

| Date | Document |
| --- | --- |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=108d06ea-5f4d-4c6c-b7ea-0d6d5fd713c2.pdf) |
| 2026-02-05 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=6966d870-0ffb-4ba7-bb60-5c39b5536a83.pdf) |
| 2025-11-06 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2d5205fe-6e49-4443-b824-043d16c7b5eb.pdf) |
| 2024-11-07 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=1356b0c9-6ee1-424c-b4e6-3967588ad2a8.pdf) |
| 2024-02-09 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=93f51f85-f9be-4985-9315-f6c8948e0c59.pdf) |
| 2023-11-09 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=410388fa-981d-4c3e-a6a7-279664f582ef.pdf) |
| 2023-11-09 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=d6c16153-5659-4c1b-b2aa-11283037ddc5.pdf) |
| 2023-08-08 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=26b8d666-ebc8-4652-be1e-4c7e6553849b.pdf) |
| 2023-05-27 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=41f58b6f-82a1-4cb5-af0a-b317e76756cb.pdf) |
| 2022-05-12 | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=4f4b1e2c-749b-4ac4-8073-a1efebb7d9c0.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=e4d4a653-51f8-4c57-861b-9fb79c97da26.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e4d4a653-51f8-4c57-861b-9fb79c97da26.pdf) |
| Feb 2023 | [Concall - Feb 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/e5b2dbd8-d76a-48b3-9a76-8b5c1a2601d3.pdf) |
| Feb 2023 | [Concall - Feb 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/92e4f686-6b42-461f-8009-4d1c5dc7c1a3.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 7 May - Q4 post-results conference call invite is enclosed herewith. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 7 May - Q4 post-results conference call invite is enclosed herewith.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/d66022d3-de83-4725-9556-db5d7b6ad510.pdf) |
| 7 May - Board to meet on May 14, 2026 to approve FY26 audited results and consider interim dividend. | [Board Meeting Intimation for Approval Of Financial Results And Declaration Of Interim Dividend, If Any, Approved By The Board. 7 May - Board to meet on May 14, 2026 to approve FY26 audited results and consider interim dividend.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/a25fb8fa-b03a-413f-b853-ad78f1755a9a.pdf) |
| 6 Apr - Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026 | [Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018 6 Apr - Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026](https://www.bseindia.com/xml-data/corpfiling/AttachHis/454b2559-54a4-47fc-9f49-53e20d2b29b8.pdf) |
| 5 May - Caplin Steriles received USFDA approval for Calcium Gluconate Injection ANDA; U.S. sales were about $71 million. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 5 May - Caplin Steriles received USFDA approval for Calcium Gluconate Injection ANDA; U.S. sales were about $71 million.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/9e24739c-46c2-4b9f-a8ad-979170187f8a.pdf) |
| 5 Feb - Earnings call audio for Q3 FY2025-26 posted on company website, February 5, 2026. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 5 Feb - Earnings call audio for Q3 FY2025-26 posted on company website, February 5, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/6966d870-0ffb-4ba7-bb60-5c39b5536a83.pdf) |
| 3 Mar - Dr C K Gariyali ceased as Independent Director effective close of business March 03, 2026, completion of second term. | [Announcement under Regulation 30 (LODR)-Cessation 3 Mar - Dr C K Gariyali ceased as Independent Director effective close of business March 03, 2026, completion of second term.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1ca5757e-59f4-4c81-b885-fc8968765264.pdf) |
| 28 Feb - Caplin Steriles received USFDA approval for Desmopressin Injection ANDA; US sales approximately $26M (12 months to Dec 2025). | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 28 Feb - Caplin Steriles received USFDA approval for Desmopressin Injection ANDA; US sales approximately $26M (12 months to Dec 2025).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/112b9297-da70-4cdd-9334-17462629ad22.pdf) |
| 27 Mar - Trading window closed from April 1, 2026 until 48 hours after audited FY2026 results declared. | [Closure of Trading Window 27 Mar - Trading window closed from April 1, 2026 until 48 hours after audited FY2026 results declared.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3385ca89-c27e-4ade-a231-9858cd8f0052.pdf) |
| 24 Feb - Caplin Steriles received USFDA final approval for Sodium Phosphates Injection; product had ~$67M US sales (12 months to Dec 2025). | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 24 Feb - Caplin Steriles received USFDA final approval for Sodium Phosphates Injection; product had ~$67M US sales (12 months to Dec 2025).](https://www.bseindia.com/xml-data/corpfiling/AttachHis/0bf66511-5a8f-4f33-a8b5-bb994bb2cc0f.pdf) |
| 21 Jan - Typographical correction: directors' effective appointment date is 2 Feb 2026, not 2025. | [Clarification Regarding Effective Date Of Appointment Mentioned In Disclosure Submitted Under Regulation 30 Of SEBI (LODR) Regulations, 2015 On 20Th January, 2026 21 Jan - Typographical correction: directors' effective appointment date is 2 Feb 2026, not 2025.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/dddba292-a43f-41a7-9934-fdd04a1740bb.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2010 from nse](https://archives.nseindia.com/annual_reports/AR_VINYLINDIA_2009_2010_03092010120000.zip) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/500e1647-d2c9-44c8-8ed7-06ba0d8af9cf.pdf) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ddea6995-29cd-4570-aa2f-c0a3691573a1.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/39847542-438c-4d28-b703-7fb4b0a1508e.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/c4026dc4-2bcc-4e07-807c-5a9d794000b6.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/4b631e73-d210-4d55-97a9-0c49a66eff82.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/524742/76779524742.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/524129/73669524129.pdf) |
| from bse | [Annual Report 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/524742/71026524742.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/524129/68892524129.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T18:56:59.615Z.